Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04377659 · ClinicalTrials.gov registry record · Phase 2
Tocilizumab for Prevention of Respiratory Failure in Patients With Severe COVID-19 Infection
A Phase 2 study, sponsored by Memorial Sloan Kettering Cancer Center.
- Terminated
- Registry status
- Phase 2
- Development phase
- 9
- Enrollment target
NCT04377659: Clinical Trial Phase 2 study, sponsored by Memorial Sloan Kettering Cancer Center.
NCT04377659 is a Phase 2 study that was terminated before completion, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 9 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (93% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04377659, a Phase 2 study, was terminated before completion, sponsored by Memorial Sloan Kettering Cancer Center.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 9 participants
- Enrollment target
Study Summary
The purpose of this study is to find out whether the study drug tocilizumab is an effective treatment for COVID-19 infection.
Primary Outcome
The primary endpoint for this cohort is progression of respiratory failure (binary yes/no while hospitalized). Progression of respiratory failure will be defined as a sustained increase in oxygen requirement (FiO2) or need for intubation/mechanical ventilation.
Interventions
- DRUG Tocilizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2020-05-01 |
| Est. Completion | 2022-10-28 |
| Phase | Phase 2 |
Why NCT04377659 stopped before completion
NCT04377659 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 9 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (93% lower).
The record links to 0 conditions, and to 1 intervention - of which Tocilizumab is the first listed.
NCT04377659 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04377659 about?
NCT04377659 is a clinical study titled "Tocilizumab for Prevention of Respiratory Failure in Patients With Severe COVID-19 Infection". The purpose of this study is to find out whether the study drug tocilizumab is an effective treatment for COVID-19 infection.
What is the current status of trial NCT04377659?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 9 participants. The study started on 2020-05-01. Estimated completion is 2022-10-28.
What interventions are being tested in trial NCT04377659?
The interventions under investigation include: Tocilizumab (DRUG).
Who is sponsoring clinical trial NCT04377659?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04377659's enrollment target sits among peer trials
9 1989th of 2000 higher than 11 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI